References
- Runcie H. Infection in a Pre-Antibiotic Era. J Anc Dis Prev Rem. 2015;3(2):125. doi: 10.4172/2329-8731.1000125
- The Nobel Prize in Physiology or Medicine 1945 [Internet]. NobelPrize.org. Available from: https://www.nobelprize.org/prizes/medicine/1945/fleming/biographical/. (cited Aug. 8, 2023)
- Czaplewski LG, Bax R, Clokie MRJ, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239–251. InternetAvailable from. doi: 10.1016/s1473-3099(15)00466-1
- Otten H. Domagk and the development of the sulphonamides. J Antimicrob Chemother. 1986;17(6):689–690. Internet. doi: 10.1093/jac/17.6.689
- World Health Organization. WHO model formulary 2008 [Internet]. 2009. Available from: https://apps.who.int/iris/handle/10665/44053. (cited Aug. 8, 2023)
- Chopra I, Roberts MC. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232–260. InternetAvailable from. doi: 10.1128/mmbr.65.2.232-260.2001
- Lemke T. Foye’s principles of medicinal chemistry. Lippincott Williams & Wilkins:Philadelphia;2008. p. 1028–1082.
- Dinos GP. The macrolide antibiotic renaissance. Br J Pharmacol. 2017;174(18):2967–2983. InternetAvailable from. doi: 10.1111/bph.13936
- sanofi-aventis U.S. Llc (Sep 2008). “NegGram Caplets (Nalidixic Acid, USP) (PDF). Food And Drug Administration. (cited Aug. 8, 2023)
- CDC – Classes of antibiotics https://arpsp.cdc.gov/resources/OAU-Antibiotic-Class-Definitions.pdf (citedAccessed Aug. 8, 2023)
- Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. BMJ. 1948;2(4588):1009–1015. InternetAvailable from. doi: 10.1136/bmj.2.4588.1009
- Spagnolo F, Rinaldi C, Sajorda DR, et al. Evolution of resistance to continuously increasing streptomycin concentrations in populations of Escherichia coli. Antimicrob Agents Chemother InternetAvailable from. 2016;60:1336–1342. doi: 10.1128/aac.01359-15
- Pseudomonas. Cystic fibrosis foundation. [Internet] https://www.cff.org/managing-cf/pseudomonas#:~:text=Pseudomonas%20are%20among%20the%20most,bacteria%20has%20been%20decreasing%2C%20however. (cited Aug. 8, 2023)
- Kyriakidis I, Vasileiou E, Pana ZD, et al. Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens. 2021;10(3):373. InternetAvailable from. doi: 10.3390/pathogens10030373
- Weiss G, Schaible UE. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. 2015;264(1):182–203. InternetAvailable from. doi: 10.1111/imr.12266
- Jamwal S, Mehrotra P, Singh A, et al. Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism. Scientific ReportsSci Rep. 2016;6(1):InternetAvailable from. doi: 10.1038/srep23089
- Zhen X, Lundborg CS, Sun X, et al. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control. 2019;8(1):InternetAvailable from. doi: 10.1186/s13756-019-0590-7
- Woolhouse M, Waugh C, Perry M, et al. Global disease burden due to antibiotic resistance – state of the evidence. J Glob Health. 2016;6(1):InternetAvailable from. doi: 10.7189/jogh.06.010306
- The Review on Antimicrobial Resistance – O’Neil J https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (cited Aug. 8, 2023)
- Idris FN, Nadzir MM. Multi-drug resistant ESKAPE pathogens and the uses of plants as their antimicrobial agents. Arch Microbiol. 2023;205(4). InternetAvailable from. doi: 10.1007/s00203-023-03455-6
- Jiang L, Lin J, Taggart CC, et al. Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections. J Interdiscip Nanomed. 2018;3(3):111–121. InternetAvailable from. doi: 10.1002/jin2.48
- Motley MP, Fries BC, Achkar JM. A new take on an old remedy: generating antibodies against multidrug-resistant Gram-negative bacteria in a Postantibiotic world. mSphere. 2017;2(5). InternetAvailable from. doi: 10.1128/msphere.00397-17
- Sekyere JO, Govinden U, Bester LA, et al. Colistin and tigecycline resistance in carbapenemase-producing Gram-negative bacteria: emerging resistance mechanisms and detection methods. J Appl Microbiol. 2016;121(3):601–617. InternetAvailable from. doi: 10.1111/jam.13169
- Zhang R, Dong N, Huang Y, et al. Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract. Emerg Microbes Infect. 2018;7:1–11. InternetAvailable from. doi: 10.1038/s41426-018-0129-7
- Wang C, Hsieh Y, Powers ZM, et al. Defeating Antibiotic-Resistant Bacteria: Exploring Alternative therapies for a Post-Antibiotic era. IJMS. 2020;21(3):1061. InternetAvailable from. doi: 10.3390/ijms21031061
- Khan AU, Maryam L, Zarrilli R. Structure, Genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol. 2017;17(1). StructureInternetAvailable from. doi: 10.1186/s12866-017-1012-8
- Ademe M, Girma F. Candida auris: From Multidrug Resistance to Pan-Resistant Strains. 2020;13:1287–1294. Available from. doi: 10.2147/idr.s249864
- Cano V, March C, Insua JL, et al. Klebsiella pneumoniaesurvives within macrophages by avoiding delivery to lysosomes. Cell Microbiol. 2015;17(11):1537–1560. InternetAvailable from. doi: 10.1111/cmi.12466
- Blair JMA, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nature Rev Microbiol. 2015;13(1):42–51. InternetAvailable from. doi: 10.1038/nrmicro3380
- Munita JM, Arias CA, Kudva IT, et al. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2). InternetAvailable from. doi: 10.1128/microbiolspec.vmbf-0016-2015
- Marturano JE, Lowery TJ, ESKAPE pathogens in bloodstream infections are associated with higher cost and mortality but can be predicted using diagnoses upon admission. Open Forum Infect Dis. 6: InternetAvailable from. 2019; 10.1093/ofid/ofz503
- Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–616. InternetAvailable from. doi: 10.1038/nrd.2017.46
- Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis. Ann internal med. 2015;162(2):81–89. InternetAvailable from. doi: 10.7326/m13-2508
- Nyazika TK, Hagen F, Machiridza T, et al. Cryptococcus neoformans population diversity and clinical outcomes of HIV-associated cryptococcal meningitis patients in Zimbabwe. J Med Microbiol. 2016;65(11):1281–1288. InternetAvailable from. doi: 10.1099/jmm.0.000354
- Gow NAR, Latgé JP, Munro CA, et al. The fungal cell wall: structure, biosynthesis, and function. Microbiol Spectr. 2017;5(3). InternetAvailable from. doi: 10.1128/microbiolspec.funk-0035-2016
- Bard M, Lees ND, Turi TG, et al. Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids. 1993;28(11):963–967. InternetAvailable from. doi: 10.1007/bf02537115
- Dadachova E, Bryan R, Apostolidis C, et al. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis. 2006;193(10):1427–1436. InternetAvailable from. doi: 10.1086/503369
- Enoch D, Ludlam H, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55(7):809–818. InternetAvailable from. doi: 10.1099/jmm.0.46548-0
- Garbino J, Kolarova L, Rohner P, et al. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine. 2002;81(6):425–433. InternetAvailable from. doi: 10.1097/00005792-200211000-00003
- Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3(11):685–702. InternetAvailable from. doi: 10.1016/s1473-3099(03)00801-6
- Hobson RP. The global epidemiology of invasive Candida infections—is the tide turning? J Hosp Infect. 2003;55(3):159–168. InternetAvailable from. doi: 10.1016/j.jhin.2003.08.012
- Richardson M. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005;56(suppl_1):i5–i11. InternetAvailable from. doi: 10.1093/jac/dki218
- Erdoğan A, Rao SSC. Small intestinal fungal overgrowth. Curr Gastroenterol Rep. 2015;17(4). InternetAvailable from. doi: 10.1007/s11894-015-0436-2
- Martins N, Ferreira ICFR, Barros L, et al. Candidiasis: Predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia. 2014;177(5–6):223–240. InternetAvailable from. doi: 10.1007/s11046-014-9749-1
- Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980;18:158–163. InternetAvailable from. doi: 10.1128/aac.18.1.158
- Nc K, Ej A, Hachem R, et al. Comparison of the efficacy of Polyenes and triazoles against Hematogenous Candida krusei infection in neutropenic mice. J Infect Dis. 1993;168(5):1311–1313. InternetAvailable from. doi: 10.1093/infdis/168.5.1311
- White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clinical Microbiology Reviews. 1998;11(2):382–402. InternetAvailable from. doi: 10.1128/cmr.11.2.382
- Ghannoum MA, Rice LB. Antifungal Agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews. 1999;12(4):501–517. InternetAvailable from. doi: 10.1128/cmr.12.4.501
- Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 1994;2(10):393–400. InternetAvailable from. doi: 10.1016/0966-842x(94)90618-1
- Edlind TD, Katiyar SK. Mutational Analysis of Flucytosine resistance in Candida glabrata. Antimicrob Agents Chemother. 2010;54:4733–4738. InternetAvailable from. doi: 10.1128/aac.00605-10
- Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359(9312):1135–1144. InternetAvailable from. doi: 10.1016/s0140-6736(02)08162-x
- Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clinl Infect Dis. 2013;56(12):1724–1732. InternetAvailable from. doi: 10.1093/cid/cit136
- Rosini R, Nicchi S, Pizza M, et al. Vaccines against antimicrobial resistance. Front Immunol. [Internet] Available from. 2020;11:11. doi: 10.3389/fimmu.2020.01048
- McEwen SA, Collignon P. Antimicrobial resistance: a one health perspective. Microbiol Spectr. 2018;6(2). InternetAvailable from. doi: 10.1128/microbiolspec.arba-0009-2017
- Bloom DE, Black S, Salisbury D, et al. Antimicrobial resistance and the role of vaccines. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2018;115:p. 12868–12871. Available from: 10.1073/pnas.1717157115
- Hall ML, Stuart JC, Voets GM, et al. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect Dis. 2010;10(12):830–831. InternetAvailable from. doi: 10.1016/s1473-3099(10)70277-2
- Ravindran S Barbara McClintock and the discovery of jumping genes. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2012;109: 20198–20199. Available from: 10.1073/pnas.1219372109
- Baker KS, Dallman TJ, Field N, et al. Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species. Nat Commun. 2018;9(1):InternetAvailable from. doi: 10.1038/s41467-018-03949-8
- Aslam B, Wang W, Arshad M, et al. Antibiotic resistance: a rundown of a global crisis. IDR InternetAvailable from. 2018;11:1645–1658. doi: 10.2147/idr.s173867
- Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nature Rev Microbiol. 2007;5(3):175–186. InternetAvailable from. doi: 10.1038/nrmicro1614
- Tedijanto C, Olesen SW, Grad YH, et al. Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2018;115. Available from: 10.1073/pnas.1810840115
- Gupta SK, Nayak RP. Dry antibiotic pipeline: regulatory bottlenecks and regulatory reforms. J Pharmacol Pharmacother. 2014;5(1):4–7. InternetAvailable from. doi: 10.4103/0976-500x.124405
- Trosset J, Carbonell P. Synthetic biology for pharmaceutical drug discovery. Drug Design Develop Therapy. 2015;6285:6285. InternetAvailable from. doi: 10.2147/dddt.s58049
- Werth BJ Overview of antibacterial drugs. [Internet] Merck Manuals Professional Edition. 2023. https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-drugs/overview-of-antibacterial-drugs. (cited Aug. 1, 2023)
- Walesch S, Birkelbach J, Jézéquel G, et al. Fighting antibiotic resistance—strategies and (pre)clinical developments to find new antibacterials. EMBO Reports. 2022;24(1):InternetAvailable from. doi: 10.15252/embr.202256033
- The Nobel prize in physiology or medicine 1908 [Internet]. NobelPrize.org: https://www.nobelprize.org/prizes/medicine/1908/ehrlich/facts/. (Accessed Aug. 8, 2023)
- Rodgers KR, Chou RC. Therapeutic monoclonal antibodies and derivatives: historical perspectives and future directions. Biotechnol Adv. 2016;34(6):1149–1158. InternetAvailable from. doi: 10.1016/j.biotechadv.2016.07.004
- Skurnik D, Roux D, Pons S, et al. Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71(4):927–935. InternetAvailable from. doi: 10.1093/jac/dkv448
- Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to Carbapenem-Resistant enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother. 2017;61(4):61. InternetAvailable from. doi: 10.1128/aac.02349-16
- Woese CR, Fox GE Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 1977;74:p. 5088–5090. Available from: 10.1073/pnas.74.11.5088
- Jiao J, Liu L, Hua Z-S, et al. Microbial dark matter coming to light: challenges and opportunities. Natl Sci Rev. 2021;8(3):InternetAvailable from. doi: 10.1093/nsr/nwaa280
- Shim H, Laurent S, Matuszewski S, et al. Detecting and quantifying changing selection intensities from time-Sampled Polymorphism data. G3: genes. G3: Genes | Genomes | Genetics. 2016;6(4):893–904. InternetAvailable from. doi: 10.1534/g3.115.023200
- Koonin EV, Wolf YI, Evolution of microbes and viruses: a paradigm shift in evolutionary biology? Front Cell Infect Microbiol. 2: InternetAvailable from. 2012; 10.3389/fcimb.2012.00119
- Traxler MF, Kolter R. Natural products in soil microbe interactions and evolution. Nat Prod Rep. 2015;32(7):956–970. InternetAvailable from. doi: 10.1039/c5np00013k
- Shim H. Feature learning of virus genome evolution with the nucleotide Skip-Gram neural network. Evol Bioinform Online. 2019;15:117693431882107. InternetAvailable from. doi: 10.1177/1176934318821072
- Kaushik D, Rathi S, Jain A. Ceftaroline: a comprehensive update. Int J Antimicrob Agents. 2011;37(5):389–395. InternetAvailable from. doi: 10.1016/j.ijantimicag.2011.01.017
- Krishnamurthy M, Moore RT, Rajamani S, et al. Bacterial genome engineering and synthetic biology: combating pathogens. BMC Microbiol. 2016;16(1):InternetAvailable from. doi: 10.1186/s12866-016-0876-3
- Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov. 2006;5(3):191–195. InternetAvailable from. doi: 10.1038/nrd1987
- Cavaco M, Castanho MARB, Neves V, The use of antibody-antibiotic conjugates to fight bacterial infections. Front Microbiol. 13: InternetAvailable from. 2022; 10.3389/fmicb.2022.835677
- Samaranayake H, Wirth T, Schenkwein D, et al. Challenges in monoclonal antibody-based therapies. Ann Med. 2009;41(5):322–331. InternetAvailable from. doi: 10.1080/07853890802698842
- Ingram JR, Schmidt FI, Ploegh HL. Exploiting nanobodies’ singular traits. Annu Rev Immunol. 2018;36(1):695–715. InternetAvailable from. doi: 10.1146/annurev-immunol-042617-053327
- Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–497. InternetAvailable from. doi: 10.1038/256495a0
- Sawada-Hirai R, Jiang I, Wang F, et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines. 2004;2(1):5. InternetAvailable from. doi: 10.1186/1476-8518-2-5
- Lu LL, Suscovich TJ, Fortune SM, et al. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46–61. InternetAvailable from. doi: 10.1038/nri.2017.106
- Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–370. InternetAvailable from. doi: 10.1038/nrc3930
- Melis JPM, Strumane K, Ruuls SR, et al. Complement in therapy and disease. Mol Immunol. 2015;67(2):117–130. InternetAvailable from. doi: 10.1016/j.molimm.2015.01.028
- Zhao P, Zhang Y, Li W, et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020;10(9):1589–1600. InternetAvailable from. doi: 10.1016/j.apsb.2020.04.012
- Pettinato MC. Introduction to Antibody-Drug conjugates. Antibodies. 2021;10(4):42. InternetAvailable from. doi: 10.3390/antib10040042
- Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–337. InternetAvailable from. doi: 10.1038/nrd.2016.268
- Mariathasan S, Tan M. Antibody–Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections. Trends Mol Med. 2017;23(2):135–149. InternetAvailable from. doi: 10.1016/j.molmed.2016.12.008
- Chau CH, Steeg PS, Figg WD. Antibody–drug conjugates for cancer. Lancet. 2019;394(10200):793–804. InternetAvailable from. doi: 10.1016/s0140-6736(19)31774-x
- Su D, Zhang D, Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency. Front Pharmacol. 12: InternetAvailable from. 2021; 10.3389/fphar.2021.687926
- Leung D, Wurst J, Liu T, et al. Antibody conjugates-recent advances and future innovations. Antibodies. 2020;9(1):2. InternetAvailable from. doi: 10.3390/antib9010002
- Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46. InternetAvailable from. doi: 10.1007/s13238-016-0323-0
- Qerqez A, Silva RP, Maynard JA. Outsmarting Pathogens with Antibody Engineering. Annu Rev Chem Biomol Eng. 2023;14(1):217–241. InternetAvailable from. doi: 10.1146/annurev-chembioeng-101121-084508
- As G, Ávila D, Hughes MK, et al. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature. 1995;374(6518):168–173. InternetAvailable from. doi: 10.1038/374168a0
- Qin Q, Líu H, He W, et al. Single domain antibody application in bacterial infection diagnosis and neutralization. Front Immunol. 2022;13. InternetAvailable from.
- Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–448. InternetAvailable from. doi: 10.1038/363446a0
- Uchański T, Pardon E, Steyaert J. Nanobodies to study protein conformational states. Curr Opin Struct Biol. 2020;60:117–123. doi: 10.1016/j.sbi.2020.01.003 InternetAvailable from.
- Koehl A, Hu H, Feng D, et al. Structural insights into the activation of metabotropic glutamate receptors. Nature. 2019;566(7742):79–84. InternetAvailable from. doi: 10.1038/s41586-019-0881-4
- Warne T, Edwards PC, Dore AS, et al. Molecular basis for high-affinity agonist binding in GPCRs. Science. 2019;364(6442):775–778. InternetAvailable from. doi: 10.1126/science.aau5595
- Drees C, Raj A, Kurre R, et al. Engineered upconversion nanoparticles for resolving protein interactions inside living cells. Angew Chem InternetAvailable from. 2016;55:11668–11672. doi: 10.1002/anie.201603028
- Traenkle B, Rothbauer U, Under the microscope: Single-Domain antibodies for Live-Cell imaging and Super-Resolution microscopy. Front Immunol. 8: InternetAvailable from. 2017; doi: 10.3389/fimmu.2017.01030
- Guizetti J, Schermelleh L, Mäntler J, et al. Cortical constriction during abscission involves helices of ESCRT-III–dependent filaments. Science. 2011;331(6024):1616–1620. InternetAvailable from. doi: 10.1126/science.1201847
- Ries J, Kaplan C, Platonova E, et al. A simple, versatile method for GFP-based super-resolution microscopy via nanobodies. Nat Methods. 2012;9(6):582–584. InternetAvailable from. doi: 10.1038/nmeth.1991
- Feng Y, Zhou Z, McDougald D, et al. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent. Nucl Med Biol. 2021;92:171–183. InternetAvailable from. doi: 10.1016/j.nucmedbio.2020.05.002
- Farasat A, Rahbarizadeh F, Ahmadvand D, et al. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin. J Liposome Res. 2019;29(1):53–65. InternetAvailable from. doi: 10.1080/08982104.2018.1430829
- Li T, Cai H, Yao H, et al. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun. 2021;12(1):InternetAvailable from. doi: 10.1038/s41467-021-24905-z
- Gaiotto T, Ramage W, Ball C, et al. Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display. Sci Rep. 2021;11(1):11. InternetAvailable from. doi: 10.1038/s41598-021-82356-4
- Weiss W, Verrips V. Nanobodies that Neutralize HIV. Vaccines. 2019;7(3):77. InternetAvailable from. doi: 10.3390/vaccines7030077
- Caljon G, Hussain S, Vermeiren L, et al. Description of a nanobody-based competitive immunoassay to detect tsetse fly exposure. PLoS negl trop dis. 2015;9(2):e0003456. InternetAvailable from. doi: 10.1371/journal.pntd.0003456
- Tremblay JM, Vazquez-Cintron E, Lam KH, et al. Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function. Toxins (Basel). 2020;12(10):611. InternetAvailable from. doi: 10.3390/toxins12100611
- Sroga P, Safronetz D, Stein D. Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases. Future Virol. 2020;15(3):195–205. InternetAvailable from. doi: 10.2217/fvl-2019-0167
- Yamada T. Therapeutic monoclonal antibodies. Keio J Med. 2011;60(2):37–46. InternetAvailable from. doi: 10.2302/kjm.60.37
- Setliff I, Shiakolas AR, Pilewski KA, et al. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell. 2019;179(7):1636–1646.e15. InternetAvailable from. doi: 10.1016/j.cell.2019.11.003
- Mood EH, Goltermann L, Brolin C, et al. Antibiotic potentiation in multidrug-resistant Gram-negative pathogenic bacteria by a synthetic peptidomimetic. ACS Infect Dis. 2021;7(8):2152–2163. InternetAvailable from. doi: 10.1021/acsinfecdis.1c00147
- Chai J, Lee CH. Management of primary and recurrent clostridium difficile infection: an update. Antibiotics. 2018;7(3):54. InternetAvailable from. doi: 10.3390/antibiotics7030054
- Shogbesan O, Poudel DR, Victor S, et al. A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients. Can J Gastroenterol Hepatol InternetAvailable from. 2018;2018:1–10. doi: 10.1155/2018/1394379
- Wang J-W, Kuo C, Kuo F, et al. Fecal microbiota transplantation: Review and update. J Formosan Med Assoc. 2019;118:S23–S31. InternetAvailable from. doi: 10.1016/j.jfma.2018.08.011
- Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005 Jan;21(1):44–50.
- Hoogmoed CG, Geertsema-Doornbusch G, Teughels W, et al. Reduction of periodontal pathogens adhesion by antagonistic strains. Oral Microbiol Immunol. 2008;23(1):43–48. InternetAvailable from. doi: 10.1111/j.1399-302x.2007.00388.x
- Ahern PP, Maloy KJ. Understanding immune–microbiota interactions in the intestine. Immunology. 2020;159(1):4–14. InternetAvailable from. doi: 10.1111/imm.13150
- Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474(7351):327–336. InternetAvailable from. doi: 10.1038/nature10213
- Ley RE, Turnbaugh PJ, Klein S, et al. Human gut microbes associated with obesity. Nature. 2006;444(7122):1022–1023. InternetAvailable from. doi: 10.1038/4441022a
- Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2007;104:p. 13780–13785. Available from: doi: 10.1073/pnas.0706625104
- González AG, Stombaugh J, Lozupone C, et al. The mind-body-microbial continuum. Dialogues Clin Neurosci. 2011;13(1):55–62. InternetAvailable from. doi: 10.31887/dcns.2011.13.1/agonzalez
- Rajer M, Segelov E. Current cancer treatment [Internet]. IntechOpen eBooks. 2020. doi: 10.5772/intechopen.83168 Available from.
- Stone V, Xu P. Targeted antimicrobial therapy in the microbiome era. Mol Oral Microbiol. 2017;32(6):446–454. InternetAvailable from. doi: 10.1111/omi.12190
- FDA – Bezlotoxumab https://www.fda.gov/search?s=Bezlotoxumab (cited Aug. 9, 2023)
- Arnoriaga-Rodríguez M, Fernández‐Real JM. Microbiota impacts on chronic inflammation and metabolic syndrome - related cognitive dysfunction. Rev Endocr Metab Disord. 2019;20(4):473–480. InternetAvailable from. doi: 10.1007/s11154-019-09537-5
- Thomas RM, Jobin C. Microbiota in pancreatic health and disease: the next frontier in microbiome research. Nat Rev Gastroenterol Hepatol. 2020;17(1):53–64. InternetAvailable from. doi: 10.1038/s41575-019-0242-7
- Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227. InternetAvailable from. doi: 10.1038/nature11053
- Hermoso JA, García JL, García P. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol. 2007;10(5):461–472. InternetAvailable from. doi: 10.1016/j.mib.2007.08.002
- Haq IU, Chaudhry WN, Akhtar MN, et al. Bacteriophages and their implications on future biotechnology: a review. Virol J. 2012;9(1):InternetAvailable from. doi: 10.1186/1743-422x-9-9
- Baral B, Phages against killer superbugs: an enticing strategy against antibiotics-resistant pathogens. Front Pharmacol. 14: InternetAvailable from. 2023; doi: 10.3389/fphar.2023.1036051
- Leshkasheli L, Kutateladze M, Balarjishvili N, et al. Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia. J Glob Antimicrob Resist. 2019;19:255–261. InternetAvailable from. doi: 10.1016/j.jgar.2019.05.005
- Abedon ST, Kuhl SJ, Blasdel B, et al. Phage treatment of human infections. Bacteriophage. 2011;1(2):66–85. InternetAvailable from. doi: 10.4161/bact.1.2.15845
- Dissanayake U, Ukhanova M, Moye ZD, et al. Bacteriophages reduce pathogenic Escherichia coli counts in mice without distorting gut microbiota. Front Microbiol. 2019;10. InternetAvailable from.
- D’herelle Service On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. Roux Resear In Microbi. 2007;158(7):553–554. InternetAvailable from. doi: 10.1016/j.resmic.2007.07.005
- Furfaro L, Payne MS, Chang BJ, Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 8: InternetAvailable from. 2018; doi: 10.3389/fcimb.2018.00376
- Rhoads DD, Wolcott R, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18(6):237–243. InternetAvailable from. doi: 10.12968/jowc.2009.18.6.42801
- Bruttin A, Brussow H. Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy. Antimicrob Agents Chemother. 2005;49(7):2874–2878. InternetAvailable from. doi: 10.1128/aac.49.7.2874-2878.2005
- Sarker SA, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology. 2012;434(2):222–232. InternetAvailable from. doi: 10.1016/j.virol.2012.09.002
- Wright A, Hawkins C, Änggård E, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistantPseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–357. InternetAvailable from. doi: 10.1111/j.1749-4486.2009.01973.x
- Abdelkader K, Gerstmans H, Saafan AE, et al. The preclinical and clinical progress of bacteriophages and their lytic enzymes: the parts are easier than the whole. Viruses. 2019;11(2):96. InternetAvailable from. doi: 10.3390/v11020096
- Castillo D, Christiansen RH, Dalsgaard I, et al. Bacteriophage resistance mechanisms in the fish pathogen flavobacterium psychrophilum: linking genomic mutations to changes in bacterial virulence factors. Appl environ microbiol. 2015;81(3):1157–1167. InternetAvailable from. doi: 10.1128/aem.03699-14
- Goldfarb T, Sberro H, Weinstock E, et al. BREX is a novel phage resistance system widespread in microbial genomes. EMBO J. 2015;34(2):169–183. InternetAvailable from. doi: 10.15252/embj.201489455
- Labrie SJ, Samson J, Moineau S. Bacteriophage resistance mechanisms. Nature Rev Microbiol. 2010;8(5):317–327. InternetAvailable from. doi: 10.1038/nrmicro2315
- Wang C, Nie T, Lin F, et al. Resistance mechanisms adopted by a salmonella typhimurium mutant against bacteriophage. Virus res. 2019;273:197759. InternetAvailable from. doi: 10.1016/j.virusres.2019.197759
- De Jonge PA, Nóbrega FL, Brouns SJJ, et al. Molecular and evolutionary determinants of bacteriophage host range. Trends Microbiol. 2019;27(1):51–63. InternetAvailable from. doi: 10.1016/j.tim.2018.08.006
- Krut O, Bekeredjian‐Ding I. Contribution of the immune response to phage therapy. J Immunol. 2018;200(9):3037–3044. InternetAvailable from. doi: 10.4049/jimmunol.1701745
- Torres‐Barceló C. The disparate effects of bacteriophages on antibiotic-resistant bacteria. Emerg Microbes Infect. 2018;7:1–12. doi: 10.1038/s41426-018-0169-z InternetAvailable from.
- Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and clostridium difficile. Annu Rev Microbiol. 2015;69(1):445–461. InternetAvailable from. doi: 10.1146/annurev-micro-091014-104115
- Theuretzbacher U, Piddock LJV. Non-traditional antibacterial therapeutic options and challenges. Cell Host & Microbe. 2019;26(1):61–72. InternetAvailable from. doi: 10.1016/j.chom.2019.06.004
- Rima M, Rima M, Fajloun Z, et al. Antimicrobial peptides: a potent alternative to antibiotics. Antibiotics. 2021;10(9):1095. InternetAvailable from. doi: 10.3390/antibiotics10091095
- Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6. InternetAvailable from.
- Lei J, Sun L, Huang S, et al. The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019 Jul 15;11(7):3919–3931. PMID: 31396309; PMCID: PMC6684887.
- Datta S, Roy A. Antimicrobial peptides as potential therapeutic agents: a review. Int J Pept Res Ther. 2021;27(1):555–577. InternetAvailable from. doi: 10.1007/s10989-020-10110-x
- Huan Y, Kong Q, Mou H, et al. Antimicrobial peptides: Classification, design, application and research progress in multiple fields. Front Microbiol InternetAvailable from. 2020;11:11. doi: 10.3389/fmicb.2020.582779
- Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 2016;44(D1):D1087–D1093. InternetAvailable from. doi: 10.1093/nar/gkv1278
- Ciumac D, Gong H, Hu X, et al. Membrane targeting cationic antimicrobial peptides. J Colloid Interface Sci. 2019;537:163–185. InternetAvailable from. doi: 10.1016/j.jcis.2018.10.103
- Cavaco M, Andreu D, Castanho MARB. The challenge of peptide proteolytic stability studies: scarce data, difficult readability, and the need for harmonization. Angew Chem Int Ed. 2021;60(4):1686–1688. InternetAvailable from. doi: 10.1002/anie.202006372
- Moravej H, Moravej Z, Yazdanparast M, et al. Antimicrobial peptides: features, action, and their resistance mechanisms in bacteria. Microbial Drug Resist. 2018;24(6):747–767. InternetAvailable from. doi: 10.1089/mdr.2017.0392
- Da Cunha NB, Cobacho NB, Viana JFC, et al. The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts. Drug Discovery Today. 2017;22(2):234–248. InternetAvailable from. doi: 10.1016/j.drudis.2016.10.017
- Kosikowska P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Patents. 2016;26(6):689–702. InternetAvailable from. doi: 10.1080/13543776.2016.1176149
- Browne K, Chakraborty S, Chen R, et al. A new era of antibiotics: the clinical potential of antimicrobial peptides. Int J Mol Sci. 2020;21(19):7047. InternetAvailable from. doi: 10.3390/ijms21197047
- Raucher D, Ryu JS. Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med. 2015;21(9):560–570. InternetAvailable from. doi: 10.1016/j.molmed.2015.06.005
- Qvit N, Rubin SJS, Urban TJ, et al. Peptidomimetic therapeutics: scientific approaches and opportunities. Drug Discovery Today. 2017;22(2):454–462. InternetAvailable from. doi: 10.1016/j.drudis.2016.11.003
- Lenci E, Trabocchi A. Peptidomimetic toolbox for drug discovery. Chem Soc Rev. 2020;49(11):3262–3277. InternetAvailable from. doi: 10.1039/d0cs00102c
- Del Gatto A, Cobb SL, Zhang J, et al. Editorial: Peptidomimetics: synthetic tools for drug discovery and development. Front Chem. 2021;9. InternetAvailable from.
- Hadjicharalambous A, Bournakas N, Newman H, et al. Antimicrobial and Cell-Penetrating Peptides: Understanding penetration for the design of novel conjugate antibiotics. Antibiotics. 2022;11(11):1636. InternetAvailable from. doi: 10.3390/antibiotics11111636
- Ye J, Liu E, Yu Z, et al. CPP-Assisted intracellular drug delivery, what is next? Int J Mol Sci. 2016;17(11):1892. InternetAvailable from. doi: 10.3390/ijms17111892
- Ruseska I, Zimmer A. Internalization mechanisms of cell-penetrating peptides. Beilstein J Nanotechnol. 2020;11:101–123. InternetAvailable from. doi: 10.3762/bjnano.11.10
- Del Río G, Trejo Perez PM, Brizuela CA. Antimicrobial peptides with cell-penetrating activity as prophylactic and treatment drugs. Biosci Rep. 2022;42(9). InternetAvailable from. doi: 10.1042/bsr20221789
- Huang X, Li G. Antimicrobial peptides and Cell-Penetrating peptides: Non-Antibiotic Membrane-Targeting strategies against bacterial infections. IDR. 2023;16:1203–1219. InternetAvailable from. doi: 10.2147/idr.s396566
- Grdiša M. The delivery of biologically active (therapeutic) peptides and proteins into cells. CMC. 2011;18(9):1373–1379. InternetAvailable from. doi: 10.2174/092986711795029591
- Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discovery Today. 2012;17(15–16):850–860. InternetAvailable from. doi: 10.1016/j.drudis.2012.03.002
- Gautam A, Chaudhary K, Kumar R, et al. In silico approaches for designing highly effective cell penetrating peptides. J Transl Med. 2013;11(1):11. InternetAvailable from. doi: 10.1186/1479-5876-11-74
- Nam SH, Park J, Koo H. Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides. Arch Pharm Res. 2023;46(1):18–34. InternetAvailable from. doi: 10.1007/s12272-022-01425-y
- Wang C, Hsieh Y, Powers ZM, et al. Defeating Antibiotic-Resistant Bacteria: Exploring Alternative therapies for a Post-Antibiotic era. IJMS. 2020;21(3):1061. InternetAvailable from. doi: 10.3390/ijms21031061
- Bazin H. Vaccinations: a history: from Lady Montagu to Jenner and genetic engineering. John Libbey Eurotext; 2011. p. 66–67, 82.
- Ligon BL. Biography: Louis Pasteur: A controversial figure in a debate on scientific ethics. Semin Pediatr Infect Dis. 2002;13(2):134–141. InternetAvailable from. doi: 10.1053/spid.2002.125138
- Hernandez LD, Racine F, Xiao L, et al. Broad coverage of genetically diverse strains of clostridium difficile by actoxumab and Bezlotoxumab predicted by in vitro neutralization and Epitope modeling. Antimicrob Agents Chemother. 2015;59(2):1052–1060. InternetAvailable from. doi: 10.1128/aac.04433-14
- Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14(11):737–738. InternetAvailable from. doi: 10.1038/nrd4770
- EMA – Zinplava https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava (cited Aug. 9, 2023)
- WHO – Antibacterial agents 2021 https://www.who.int/publications/i/item/9789240047655 (cited Aug. 9, 2023)
- Reltecimod https://clinicaltrials.gov/study/NCT02469857 (cited Aug. 9, 2023)
- FDA – Bebtelovimab https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains (cited Aug. 9, 2023)
- Bebtelovimab – Approval revoked https://adisinsight.springer.com/drugs/800063564 (cited Aug. 9, 2023)
- CDC – Ebola mAbs https://www.cdc.gov/vhf/ebola/treatment/index.html#:~:text=The%20first%20drug%20approved%20in,was%20approved%20in%20December%202020 (cited Aug. 9, 2023)
- FDA – Inmazeb https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus (cited Aug. 9, 2023)
- FDA – Ebanga https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-ebola-virus (cited Aug. 9, 2023)
- FDA – Beyfortus https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers#:~:text=Monoclonal%20antibodies%20are%20laboratory%2Dmade,protection%20during%20the%20RSV%20season (cited Aug. 9, 2023)
- Beyfortis status https://adisinsight.springer.com/drugs/800040460 (cited Aug. 9, 2023)
- TRL1068 trials https://www.clinicaltrials.gov/search?rank=2&term=TRL1068 (cited Aug. 9, 2023)
- Trellis Bioscience – News https://www.trellisbio.com/ (cited Aug. 9, 2023)
- Mycograb trials https://www.clinicaltrials.gov/study/NCT00324025?rank=1&term=Mycograb (cited Aug. 9, 2023)
- Novartis official announcement https://www.evaluate.com/vantage/articles/news/novartis-reveals-cost-failure (cited Aug. 9, 2023)
- Aurograb trials https://classic.clinicaltrials.gov/ct2/show/NCT00217841 (cited Aug. 9, 2023)
- Mazumdar S. Raxibacumab. MAbs. 2009;1(6):531–538. [Internet] Available from. doi: 10.4161/mabs.1.6.10195
- Hou AW, Morrill AM. Obiltoxaximab: adding to the treatment Arsenal for Bacillus anthracis infection. Ann Pharmacother. 2017;51(10):908–913. InternetAvailable from. doi: 10.1177/1060028017713029
- Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent patents on anti-infective drug discovery. 2008;3(1):10–33. InternetAvailable from. doi: 10.2174/157489108783413173
- KB001A status - https://adisinsight.springer.com/drugs/800026444 (cited Aug. 9, 2023)
- 9MW1411 trials https://www.clinicaltrials.gov/study/NCT05339802?rank=1&term=9MW1411 (cited Aug. 9, 2023)
- Zurawski DV, McLendon MK. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics. 2020;9(4):155. doi: 10.3390/antibiotics9040155
- PolyCAb status - https://adisinsight.springer.com/drugs/800044829 (cited Aug. 9, 2023)
- TAC (RG7861) trials - https://www.clinicaltrials.gov/study/NCT03162250?rank=2&term=DSTA4637S (cited Aug. 9, 2023)
- VXD-003 status - https://adisinsight.springer.com/drugs/800047912 (cited Aug. 9, 2023)
- LMN-101 trials - https://www.clinicaltrials.gov/study/NCT04182490?rank=2&term=LMN-101 (cited Aug. 9, 2023)
- Pagimaximab status - https://adisinsight.springer.com/drugs/800018938 (cited Aug. 9, 2023)
- Pagimaximab trials - https://clinicaltrials.gov/study/NCT00631800?term=BSYX-a110&rank=3 (cited Aug. 9, 2023)
- NTM-1632 trials - https://clinicaltrials.gov/study/NCT02779140?term=NTM-1632&rank=1 (cited Aug. 9, 2023)
- IM-01 trials - https://www.clinicaltrials.gov/study/NCT04121169?rank=1&term=NCT04121169 (cited Aug. 9, 2023)
- Integrated biotherapeutics cd-ISTAb - https://www.integratedbiotherapeutics.com/our-science/ (cited Aug. 9, 2023)
- F598 status - https://adisinsight.springer.com/drugs/800028083 (cited Aug. 9, 2023)
- Pritoxaximab/Setoxaximab status - https://adisinsight.springer.com/drugs/800018938 (cited Aug. 9, 2023)
- ASN-4/ASN-5 status - https://adisinsight.springer.com/drugs/800033758 (cited Aug. 9, 2023)
- DiGiandomenico A, Keller A, Gao C, et al. A multifunctional bispecific antibody protects againstPseudomonas aeruginosa. Sci, trans med. 2014;6(262):InternetAvailable from. doi: 10.1126/scitranslmed.3009655
- Hua L, Hilliard JJ, Shi Y, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother. 2014;58(2):1108–1117. InternetAvailable from. doi: 10.1128/aac.02190-13
- Pharmaceuticals - Aerumab A https://www.aridispharma.com/ar-101/ (cited Aug. 9, 2023)
- Aridis Pharmaceuticals - AR-301 https://www.aridispharma.com/ar-301/ (Accessed Aug. 9, 2023)
- Aridis Pharmaceuticals - AR-401 https://www.aridispharma.com/ar-105/ (cited Aug. 9, 2023)
- Aridis Pharmaceuticals - AR-401 https://www.aridispharma.com/ar-401/ (cited Aug. 9, 2023)
- Hilchie AL, Wuerth K, Hancock REW. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol. 2013;9(12):761–768. InternetAvailable from. doi: 10.1038/nchembio.1393
- Seres therapeutics - SER-109 https://www.serestherapeutics.com/our-programs/ (cited Aug. 10, 2023).
- Rebiotix - REBYOTA https://www.rebyota.com/what-is-rebyota/ (cited Aug. 10, 2023).
- Butler MS, Gigante V, Sati H, et al. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother. 2022;66(3):InternetAvailable from. doi: 10.1128/aac.01991-21
- SYN-004 trials - https://www.clinicaltrials.gov/study/NCT02563106?rank=6&term=SYN-004 (cited Aug. 10, 2023).
- VE-303 trials - https://www.clinicaltrials.gov/study/NCT03788434?rank=4&lead=Vedanta%20Biosciences,%20Inc. (cited Aug. 10, 2023).
- Finch Therapeutics - CP101 https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-provides-update-its-phase-3-trial-cp101 (cited Aug. 10, 2023).
- CP101 trials - https://www.clinicaltrials.gov/study/NCT05153499?rank=5&term=CP101 cited Aug. 10, 2023).
- DAV-132 status - https://adisinsight.springer.com/drugs/800066733 (cited Aug. 10, 2023).
- MET-2 trials - https://www.clinicaltrials.gov/study/NCT02865616?rank=1&term=MET2 (cited Aug. 10, 2023).
- NuBiyota – MET-2 https://nubiyota.com/pipeline/ (cited Aug. 10, 2023).
- RBX7455 trials - https://www.clinicaltrials.gov/study/NCT02981316?rank=2&term=RBX7455 (Accessed Aug. 10, 2023).
- Rodriguez-Castaño GP, Rosenau F, Ständker L, et al. Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically Important Candida Species. Pharmaceutics. 2023;15(3):789. InternetAvailable from. doi: 10.3390/pharmaceutics15030789
- SVT-1C469 status - https://adisinsight.springer.com/drugs/800060546 (Accessed Aug. 10, 2023).
- VP-20621 status - https://adisinsight.springer.com/drugs/800023964 (Accessed Aug. 10, 2023).
- Spexisbio - POL7080. https://spexisbio.com/impv/ (Accessed Aug. 10, 2023).
- Groo A-C, Matougui N, Umerska A, et al. Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide. IJN InternetAvailable from. 2018;13:7565–7574. doi: 10.2147/ijn.s180040
- Adenium biotech – AP-139 http://adeniumbiotech.com/pipeline (Cited Oct. 30, 2015).
- Adenium biotech – AP-114 https://adisinsight.springer.com/drugs/800039698 (cited Aug. 10, 2023).
- NVB302 status - https://www.technologynetworks.com/drug-discovery/news/novacta-completes-phase-i-study-of-nvb302-203745 (Accessed Aug. 10, 2023).
- NVB302 status - https://adisinsight.springer.com/drugs/800030483 (Accessed Aug. 10, 2023).
- SPR-206 status - https://adisinsight.springer.com/drugs/800056049 (Accessed Aug. 10, 2023).
- MRX-8 status - https://adisinsight.springer.com/drugs/800056049 (Accessed Aug. 10, 2023).
- QPX-9003 status - https://adisinsight.springer.com/drugs/800054735 (Accessed Aug. 10, 2023).
- Omiganan trials – https://www.clinicaltrials.gov/study/NCT00231153?rank=1&term=NCT00231153 (Accessed Aug. 11, 2023).
- Ropocamptide trials – https://www.clinicaltrials.gov/study/NCT04098562?rank=1&term=NCT04098562 (Accessed Aug. 11, 2023).
- Iseganan trials – https://www.clinicaltrials.gov/study/NCT00118781?rank=1&term=NCT00118781 (Accessed Aug. 11, 2023).
- PAC-113 trials – https://www.clinicaltrials.gov/study/NCT00659971?rank=1&term=NCT00659971 (Accessed Aug. 11, 2023).
- Lactoferrin 1 11 trials – https://www.clinicaltrials.gov/study/NCT00509834?rank=1&term=NCT00509834 (Accessed Aug. 11, 2023).
- Talactoferrin alfa trials – https://www.clinicaltrials.gov/study/NCT01273779?rank=1&term=NCT01273779 (Accessed Aug. 11, 2023).
- Exeporfinium chloride trials – https://www.clinicaltrials.gov/study/NCT03915470?rank=1&term=NCT03915470 (Accessed Aug. 11, 2023).
- WLBU2 trials – https://www.clinicaltrials.gov/study/NCT05137314?rank=1&term=NCT05137314 (Accessed Aug. 11, 2023).
- p. LSVT-1701– https://www.biospace.com/article/releases/intron-is-finalizing-the-sal200-tech-transfer/ (Accessed Aug. 11, 2023).
- Hoogmoed CG, Geertsema-Doornbusch G, Teughels W, et al. Reduction of periodontal pathogens adhesion by antagonistic strains. Oral Microbiol Immunol. 2008;23(1):43–48. InternetAvailable from. doi: 10.1111/j.1399-302x.2007.00388.x
- Bae J, Jun KI, Kang CK, et al. Efficacy of Intranasal administration of the recombinant endolysin SAL200 in a lethal murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother. 2019;63(4):InternetAvailable from. doi: 10.1128/aac.02009-18
- Schuch R, Lee HM, Schneider B, et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus–induced murine bacteremia. J Infect Dis. 2014;209(9):1469–1478. InternetAvailable from. doi: 10.1093/infdis/jit637
- Conrafect - Exebacase https://www.contrafect.com/pipeline/exebacase (Accessed Aug. 12, 2023).
- Bacteriophage trials – https://www.clinicaltrials.gov/study/NCT04287478?term=Phage&aggFilters=phase:0%201%202&lead=Adaptive%20Phage%20Therapeutics,%20Inc.&rank=5 (Accessed Aug. 12, 2023).
- LBP-EC01 trials - https://www.clinicaltrials.gov/study/NCT05488340?rank=2&term=LBP-EC01 (Accessed Aug. 12, 2023).
- Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35–45. InternetAvailable from. doi: 10.1016/s1473-3099(18)30482-1
- Bacteriophage cocktail trials - https://classic.clinicaltrials.gov/ct2/show/NCT02116010 (Accessed Aug. 12, 2023).
- Shim H. Three innovations of next-generation antibiotics: evolvability, specificity, and non-immunogenicity. Antibiotics. 2023;12(2):204. doi: 10.3390/antibiotics12020204
- AP-PA-02 trials - https://clinicaltrials.gov/study/NCT04596319 (Accessed Aug. 12, 2023).
- YPT-10 trials – https://www.clinicaltrials.gov/study/NCT04684641?rank=1&term=NCT04684641 (Accessed Aug. 12, 2023).
- BX004-A trials – https://www.clinicaltrials.gov/study/NCT05010577?rank=1&term=NCT05010577 (Accessed Aug. 12, 2023).
- LMN-201 – https://www.clinicaltrials.gov/study/NCT05330182?rank=1&term=NCT05330182 (Accessed Aug. 12, 2023).
- Armata Pharma – p. AmpliPhage–004/001 https://www.armatapharma.com/pipeline/pipeline-overview/ (Accessed Aug. 12, 2023).
- Armata pharma – p. AmpliPhage–004 https://adisinsight.springer.com/drugs/800039161 (Accessed Aug. 12, 2023).
- Armata Pharma – p. AmpliPhage–001 https://adisinsight.springer.com/drugs/800049687 (Accessed Aug. 12, 2023).
- PT-3.1 status - https://adisinsight.springer.com/drugs/800027172 (Accessed Aug. 13, 2023).
- Cass J, Cullen S, Castillo AL, et al. Saspject: a novel antibacterial technology targeting MDR Pseudomonas aeruginosa demonstrating a low propensity for resistance development. Interscience Conference of Antimicrobial Agents and Chemotherapy; Washington, DC; Sep 5–9, 2014p. F–1550.
- Kulkarni NN, Yi Z, Huehnken C, et al. Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: linkage to inflammatory and growth factor cytokines pathways. Mol Immunol. 2015;63(2):530–539. InternetAvailable from. doi: 10.1016/j.molimm.2014.10.007
- Raqib R, Sarker P, Bergman P, et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2006;103:p. 9178–9183. Available from: 10.1073/pnas.0602888103
- Bergman P, Norlin A-C, Hansen S, et al. Vitamin D3supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. BMJ Open. 2012;2(6):e001663. InternetAvailable from. doi: 10.1136/bmjopen-2012-001663
- Rhu-pGSN trials - https://www.clinicaltrials.gov/study/NCT05947955?term=rhu%20pgsn&aggFilters=phase:0%201%202&spons=BioAegis%20Therapeutics%20Inc.&rank=2 (Accessed Aug. 13, 2023).
- CYT-107 trials - https://clinicaltrials.gov/study/NCT04154826?term=CYT-107&rank=8 (Accessed Aug. 13, 2023).
- CYT-107 status - https://adisinsight.springer.com/drugs/800020133 (Accessed Aug. 13, 2023).
- C. Difficile Toxoid Vaccine - https://www.sanofi.com/en/media-room/press-releases/2017/2017-12-01-21-00-00-1216392 (Accessed Aug. 13, 2023).
- Westritschnig K, Hochreiter R, Wallner G, et al. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of aPseudomonas aeruginosahybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Human Vaccines Immunother InternetAvailable from. 2013;10:170–183. doi: 10.4161/hv.26565
- IC84 status - https://valneva.com/research-development/clostridium-difficile/ (Accessed Aug. 13, 2023).
- Scully IL, Timofeyeva Y, Illenberger A, et al. Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease. Microorganisms. 2021;9(1):177. InternetAvailable from. doi: 10.3390/microorganisms9010177
- SA4Ag - https://www.pfizer.com/news/press-release/press-release-detail/independent_data_monitoring_committee_recommends_discontinuation_of_the_phase_2b_strive_clinical_trial_of_staphylococcus_aureus_vaccine_following_planned_interim_analysis
- SA4Ag trials - https://classic.clinicaltrials.gov/ct2/show/NCT02388165?term=SA4AG&draw=2&rank=1 (Accessed Aug. 13, 2023).
- CAL-02 status - https://adisinsight.springer.com/drugs/800043643 (Accessed Aug. 13, 2023).
- Ftortiazinon status - https://www.clinicaltrials.gov/study/NCT03638830?rank=1&term=Ftortiazinon (Accessed Aug. 13, 2023).
- OligoG trials - https://www.clinicaltrials.gov/study/NCT03698448?rank=1&term=NCT03698448 (Accessed Aug. 13, 2023).
- Pritchard MF, Powell LC, Khan S, et al. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Sci Rep. 2017;7(1):InternetAvailable from. doi: 10.1038/srep44731
- BVL-GSK098 status - https://adisinsight.springer.com/drugs/800060204 (Accessed Aug. 13, 2023).
- BVL-GSK098 trials - https://www.clinicaltrials.gov/study/NCT05473195?rank=2&term=BVL-GSK098 (Accessed Aug. 13, 2023).
- GSK3882347 status - https://adisinsight.springer.com/drugs/800059774 (Accessed Aug. 13, 2023).
- ALS-4 status - https://adisinsight.springer.com/drugs/800055790 (Accessed Aug. 13, 2023).
- Bacteriophage commercialization example - https://phylabiotics.com/pages/phyla-nift (Accessed Aug. 14, 2023).
- Chang RYK, Nang SC, ChanH-K, et al. Novel antimicrobial agents for combating antibiotic-resistant bacteria. Adv Drug Delivery Rev. 2022;187:114378. InternetAvailable from. doi: 10.1016/j.addr.2022.114378
- FDA-FMT 2019 advisory https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission (Accessed Aug. 14, 2023).
- FDA-FMT first approval https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product (Accessed Aug. 14, 2023).
- FDA-FMT second approval https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides (Accessed Aug. 14, 2023).
- G7 Health Ministers’ Communiqué, 20 May 2022, Berlin -World. (2022, May 20). ReliefWeb. https://reliefweb.int/report/world/g7-health-ministers-communique-20-may-2022-berlin (Accessed Aug. 14, 2023).
- Incentivising the development of new antibacterial treatments: progress report by the global AMR R&D hub and WHO 2023 – global AMR R&D hub. (n.d.). https://globalamrhub.org/news-events/news/incentivising-the-development-of-new-antibacterial-treatments-progress-report-by-the-global-amr-rd-hub-and-who-2023/ (Accessed Aug. 14, 2023).
- World Health Organization: WHO. Urgent call for better use of existing vaccines and development of new vaccines to tackle AMR. WHO International News [Internet]. 2022 Jul 12; Available from: https://www.who.int/news/item/12-07-2022-urgent-call-for-better-use-of-existing-vaccines-and-development-of-new-vaccines-to-tackle-amr (Accessed Sept. 28, 2023).
- Antimicrobial resistance [Internet]. 2021. https://www.who.int/teams/immunization-vaccines-and-biologicals/product-and-delivery-research/anti-microbial-resistance (Accessed Aug. 28, 2023).
- University of Birmingham. BactiVac funded to develop bacterial vaccines in global fight against antimicrobial resistance. University Of Birmingham [Internet]: cited 2023 Sep 28; https://www.birmingham.ac.uk/news/2023/bactivac-backed-to-develop-bacterial-vaccines-in-global-fight-against-antimicrobial-resistance ( Accessed Sept. 29, 2023).
- IVI-led CAPTURA consortium wins fleming fund award for work on antimicrobial resistance (AMR) data across Asia. [Internet] IVI. 2019. Available from: https://www.ivi.int/ivi-led-captura-consortium-wins-fleming-fund-award-for-work-on-antimicrobial-resistance-amr-data-across-asia/ ( Accessed Sept. 29, 2023).
- Rex JH, Lynch HF, Cohen IG, et al. Designing development programs for non-traditional antibacterial agents. Nat Commun. 2019;10(1):InternetAvailable from. doi: 10.1038/s41467-019-11303-9
- Rex J, – ASM Podcast, https://asm.org/Podcasts/Editors-in-Conversation/Episodes/Developing-Non-Traditional-Antibiotics-EIC-23 (Accessed Jul. 15, 2023)